FOUR INNOVATIVE DRUGS OF HANSOH PHARMACEUTICAL GROUP HAVE BEEN RENEWED IN THE NATIONAL REIMBURSEMENT DRUG LIST (2024 VERSION)
On November 28, 2024, Hansoh Pharmaceutical Group Company Limited announced that the following four innovative drugs of the Group had been renewed inthe National Reimbursement Drug List (2024 Version) (the “2024 NRDL”) published by China’s National Healthcare Security Administration and the Ministry of Human Resources and Social Security. The 2024 NRDL will be officially implemented on January 1, 2025.
1. Aumolertinib Mesilate Tablets (trade name: Ameile阿美乐®) is the first domestic innovative third-generation epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) drug independently developed by Hansoh, and its two approved indications have been renewed in the 2024 NRDL:
•The first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors have EGFR exon 19 deletions or exon 21(L858R) substitute mutation.
•The treatment of locally advanced or metastatic NSCLC in adult patients who have progressed on or after EGFR-TKI therapy, and have been confirmed to have EGFR T790M mutation positivity through testing.
2. Flumatinib Mesylate Tablets (trade name: Hansoh Xinfu云顶国际昕福®) is China’ s first domestic innovative second-generation Bcr-Abl TKI drug independently developed by Hansoh, and is used to treat adult patients with Philadelphia chromosome positive chronic myelogenous leukemia (Ph+CML) in the chronic phase.
3. Inebilizumab Injection (trade name: XINYUE昕越®) is a targeted CD19 B-cell depleting antibody for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are AQP4 antibody-positive.
4. PEG-Loxenatide for Injection (trade name: Fulaimei孚来美®) is the first innovative drug derived from Hansoh’s proprietary PEGylation technology, it is China’s first domestic innovative GLP-1RA weekly dosage form formulation, used for patients with BMI ≥ 25 who have poor oral hypoglycemic drugs such as metformin or insulin control effects.
Additionally, the innovative drugs Pegmolesatide Injection (trade name: Saint Luolai圣罗莱®) and Tenofovir Amibufenamide Tablets (trade name: Hengmu恒沐®) were included in the 2023 NRDL and they are currently within the agreement period, with the agreement valid until December 31, 2025; Morinidazole Sodium Chloride for Injection (trade name: Mailingda迈灵达®) has been included in category B of general list of the NRDL. All indications for the innovative drugs launched by Hansoh are included in the NRDL, which helps to further improve the affordability and accessibility of the innovative drugs among patients.
Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, anti-infectives, central nervous system (CNS), metabolism and immunology. Hansoh Pharma has launched 7 innovative drugs that generate product sales in China, with the revenue from innovative drugs and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK).
1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
